Lisata Therapeutics, Inc.
lisata.com
Actively hiring
Biotechnology
Health Care
Prescription Drugs
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
1-10
employees, estimated range
Backers
1
Kyoto University Innovation Capital
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Backed byfrom the funds' portfolios and accelerator catalogs
Kyoto University Innovation Capital Investors in similar startupsfunds that back the companies most like this one
backs Validproof
backs Lundbeck
Similar startupsby what they do, their industry and backers
Validproof assists pharmaceutical companies meet their traceability obligation and ensure that their medicine makes it into the right hands.
PleoPharma pharmaceutical company homepage, management team, product offering, contact us.
Together for Health. Noucor Completes Acquisition of HELM Pharmaceutical.
LifeMine is a clinical-stage biopharmaceutical company pioneering a bold new approach, Top-Down Drug DiscoveryTM, which leverages…
Headquartered in Copenhagen, Denmark, H. Lundbeck A/S is a global biopharmaceutical company dedicated exclusively to brain health and…
Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics. Our approach enables selective modulation…
Overview
Lisata is a clinical-stage pharmaceutical company dedicated to improving lives through the discovery, development, and commercialization of innovative medicines.
News
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz PharmExec
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
Read more
Report
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
SOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (
Read more
Report
Lisata Therapeutics Acquires Marea Therapeutics And Raises $225 Million To Advance Cardioendocrine Drug Pipeline
Lisata Therapeutics has acquired Marea Therapeutics in a stock-for-stock transaction and secured a concurrent oversubscribed $225 million private placement as the combined company shifts its focus toward developing next-generation treatments for cardioend
Read more
Report
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseasesMarea has multiple late-stage clinica...
Read more
Report
Lisata Therapeutics acquires Marea Therapeutics, secures $225 million private placement
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has acquired Marea Therapeutics, a clinical-stage biotech developing next-generation medicines for cardioendocrine diseases. The companies also entered a private placement financing agreement expected to rais
Read more
Report
Lisata Therapeutics Acquires Marea Therapeutics; Announces Concurrent Private Placement
Lisata Therapeutics (LSTA) has acquired Marea Therapeutics, a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop next-generation medicines for cardioendocrine diseases.
Read more
Report
Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer
--Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that it has entered into a binding term sheet to be acquired by Kuv
Read more
Report
Exclusive BAC Article: Lisata Therapeutics; Phase 2b ASCEND Data Release, Cohort B Data In 2025, Phase 3 Study Possible 2026 And Catalysts (NASDAQ:LSTA)
I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be Lisata Therapeutics (LSTA).
Read more
Report